Details of completed HTA project
Last updated: 9 May 2012 - Next update due: 16 May 2012
Research type: |
NICE Technology Assessment Report (TAR) |
Project title: |
The clinical and cost-effectiveness of trastuzumab and vinorelbine for breast cancer. |
Link to NICE guidance page |
|
Special notes |
Completed - No publication. The work from this report has been updated and is due to be published by two separate projects: project 00/15/02 and project 00/15/03 |
Project ref: |
00/15/01 |
Cost: |
This project has been commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis. |
Chief Investigator : |
Centre for Reviews and Dissemination (CRD), University of York |
Start Date: |
November 2000 |
Estimated date of publication in HTA journal series: |
Completed - No publication required in the HTA monograph series. |
Project Abstract: |
The objectives of the review are to evaluate the clinical effectiveness and cost-effectiveness of trastuzumab (Herceptin ®, Genentech, Inc., South San Fransisco, California) and vinorelbine (Navelbine®, Burroughs Wellcome Co, Research triangle Park, NC; Pierre Fabre Medicament, Paris, France) in the management of breast cancer. Information relating to the two drugs will be presented separately. Only randomised controlled trials of the drugs alone or in combination with other agents versus systemic therapy without the drugs, will be considered in the assessment of clinical effectiveness. The assessment of cost effectiveness will only include full economic evaluations (cost effectiveness analyses, cost-utility analyses and cost-benefit analyses). The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence. Details of the appraisal timetable and processes can be found at the <a href=http://www.nice.org.uk/nice-web/Embcat.asp?page=oldsite/conf/app_a.htm> NICE website</a> |
MeSH* index primary terms: |
HERCEPTIN Q-therapeutic-use; ANTINEOPLASTIC-AGENTS Q-therapeutic-use; BREAST-NEOPLASMS Q-therapeutic-use; VINORELBINE Q-therapeutic-use |
MeSH* index secondary terms: |
HUMAN; RANDOMIZED-CONTROLLED-TRIAL; CLINICAL-TRIAL; HERCEPTIN Q-economics; ANTINEOPLASTIC-AGENTS Q-economics; BREAST-NEOPLASMS Q-economics; VINORELBINE Q-economics; COST-BENFIT-ANALYSIS; FEMALE |
NRR* number, if applicable: |
N0484094182 (*National Research Register). The National Research Register was a public database of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health Service (NHS). It is now an archive of projects from early 2000 to September 2007. Search the NRR archive. |
Project Protocol: |
Project protocol not available |
URL of this page: |
http://www.hta.ac.uk/1202 |
News feeds